Creelan, Benjamin C. http://orcid.org/0000-0002-2728-8070
Yeh, Tammie C.
Kim, Sang-We
Nogami, Naoyuki
Kim, Dong-Wan
Chow, Laura Q. M.
Kanda, Shintaro
Taylor, Rosemary
Tang, Weifeng
Tang, Mei
Angell, Helen K.
Roudier, Martine P.
Marotti, Marcelo
Gibbons, Don L. http://orcid.org/0000-0003-2362-3094
Funding for this research was provided by:
AstraZeneca PLC
Article History
Received: 1 May 2020
Revised: 28 August 2020
Accepted: 7 September 2020
First Online: 5 October 2020
Ethics approval and consent to participate
: This study was performed in accordance with ethical principles that have their origin in the Declaration of Helsinki and are consistent with the International Conference on Harmonisation (ICH)/Good Clinical Practice (GCP) guidelines, applicable regulatory requirements and the AstraZeneca policy on Bioethics and Human Biological Samples. All patients provided written informed consent, including for exploratory biomarker research. The study protocol, and all other written information and/or materials provided to patients, were approved by the following Ethics Committees/Institutional Review Boards: National Cancer Center Hospital, Chuo-ku, Japan; National Hospital Organization Shikoku Cancer Center, Matsuyama-shi, Japan; Seoul National University Hospital, Seoul, South Korea; Asan Medical Center, Seoul, South Korea; Liberty Institutional Review Board, DeLand, USA; MD Anderson Cancer Center, Houston, USA; Western Institutional Review Board, Puyallup, USA.
: Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca’s data sharing policy described atExternalRef removed.
: B.C.C. has received institutional research grants/supplies from Biodesix, Boehringer Ingelheim, Bristol-Myers Squibb, Iovance Biotherapeutics, Neogenomics and Prometheus; participated in speaker bureaus for Achilles, AstraZeneca, Bristol-Myers Squibb, Foundation Medicine, F. Hoffmann-La Roche AG, Gilead and Takeda; and has participated in advisory boards for AbbVie, BergenBio, Bristol-Myers Squibb and GlaxoSmithKline. T.C.Y., R.T., W.T. and H.K.A. are employees or contracted employees of AstraZeneca and may be shareholders of AstraZeneca. S.-W.K. has received clinical research support from AstraZeneca, Boehringer Ingelheim and Eli Lilly. N.N. has received research grants from AstraZeneca, Boehringer Ingelheim, Chugai Pharmaceutical, Kyowa Hakko Kirin, ONO Pharmaceutical and Taiho Pharmaceutical and personal fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical, Eli Lilly Japan, Kyowa Hakko Kirin, Meiji Seika Pharma, Merck Sharp & Dohme, Nikkei Business Publications, ONO Pharmaceutical, Pfizer Japan, Reno Medical and Taiho Pharmaceutical. D.-W.K’s institution has received research funding from Alpha Biopharma, AstraZeneca/MedImmune, Hanmi, Janssen, Merus, Mirati Therapeutics, MSD, Novartis, ONO Pharmaceutical, Pfizer Inc., Roche/Genentech, Takeda, TP Therapeutics, Xcovery and Yuhan. L.Q.M.C. is an employee of the University of Texas, Austin and a former employee of the University of Washington/Seattle Cancer Care Alliance. L.Q.M.C’s institution has received research funding from Alkermes, AstraZeneca/MedImmune, Bristol-Myers Squibb, Dynavax, Eli Lilly, Genentech, Incyte, Merck, Novartis, Pfizer Inc., Seattle Genetics and VentiRx; and the University of Washington/Seattle Cancer Care Alliance received institutional funding from AstraZeneca for this study. L.Q.M.C. has received honoraria from Amgen and has participated in advisory boards for Alkermes, Amgen, AstraZeneca, Bristol-Myers Squibb, Dynavax, Genentech, Merck, Novartis, Pfizer Inc., Sanofi Genzyme, Seattle Genetics, Synthorx and Takeda. S.K. has received research grant funding from AbbVie, AstraZeneca and ONO Pharmaceutical; honoraria from AstraZeneca, Bristol-Myers Squibb, Chugai Pharmaceutical, Novartis and ONO Pharmaceutical; and has participated in advisory boards for AstraZeneca. M.T. is an employee of Astellas Pharma US and a former employee of AstraZeneca. M.P.R. is an employee of the Institute for Prostate Cancer Research and a former employee of AstraZeneca. M.M. is a former employee of AstraZeneca. D.L.G. has received research grants from AstraZeneca, Janssen Research & Development and Takeda; has participated in advisory boards for AstraZeneca, GlaxoSmithKline and Sanofi; and has received travel expenses from AstraZeneca. D.L.G’s institution has received compensation for conducting the study.
: This study was sponsored by AstraZeneca PLC.